Understanding ITGB7: Potential Drug Target Or Biomarker for Cancer

Target Name: ITGB7

NCBI ID: G3695

ITGB7

Understanding ITGB7: Potential Drug Target Or Biomarker for Cancer

ITGB7 (Integrin beta 7) is a protein that is expressed in the endothelial cells of the body, which play a critical role in maintaining blood flow and the supply of oxygen and nutrients to the body's tissues. ITGB7 is also expressed in various types of cancer cells, which makes it an attractive drug target for researchers looking for new treatments for cancer.

One of the main functions of ITGB7 is its role in cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs, and ITGB7 plays a key role in this process. ITGB7 helps to stick together the cells that make up the endothelial layer, which forms the lining of the blood vessels. This helps to maintain the integrity of the blood vessels and ensure that they remain open and able to deliver oxygen and nutrients to the body's tissues.

In addition to its role in cell adhesion, ITGB7 has also been shown to play a key role in the regulation of cell growth and differentiation. ITGB7 has been shown to promote the growth and development of various types of cancer cells, and it has also been shown to contribute to the development and progression of various types of cancer.

ITGB7 has also been shown to be involved in the regulation of the immune response. ITGB7 has been shown to interact with the immune system and to play a role in the regulation of immune cell function. This makes ITGB7 an attractive target for researchers looking for new treatments for cancer that target the immune system.

In addition to its potential as a drug target, ITGB7 is also a potential biomarker for cancer. Because ITGB7 is expressed in various types of cancer cells, it has been shown to be a useful marker for tracking the development and progression of cancer. This makes ITGB7 an attractive target for researchers looking for new diagnostic tests for cancer.

Overall, ITGB7 is a protein that has the potential to be a drug target or biomarker for cancer. Further research is needed to fully understand its role and to develop new treatments for cancer.

Protein Name: Integrin Subunit Beta 7

Functions: Integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT). Integrin alpha-4/beta-7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interacts also with VCAM1 and fibronectin, an extracellular matrix component. It recognizes one or more domains within the alternatively spliced CS-1 region of fibronectin. Interactions involves the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. Binds to HIV-1 gp120, thereby allowing the virus to enter GALT, which is thought to be the major trigger of AIDS disease. Interaction would involve a tripeptide L-D-I in HIV-1 gp120. Integrin alpha-E/beta-7 (HML-1) is a receptor for E-cadherin

The "ITGB7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets